These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 25879549

  • 1. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
    Fan D, Li Z, Zhang X, Yang Y, Yuan X, Zhang X, Yang M, Zhang Y, Xiong D.
    J Hematol Oncol; 2015 Feb 28; 8():18. PubMed ID: 25879549
    [Abstract] [Full Text] [Related]

  • 2. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE.
    Cancer Res; 2002 Mar 15; 62(6):1730-6. PubMed ID: 11912147
    [Abstract] [Full Text] [Related]

  • 3. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 4. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M.
    Clin Cancer Res; 2017 Jul 01; 23(13):3385-3395. PubMed ID: 28096272
    [Abstract] [Full Text] [Related]

  • 5. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.
    Cell Stem Cell; 2009 Jul 02; 5(1):31-42. PubMed ID: 19570512
    [Abstract] [Full Text] [Related]

  • 6. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S.
    Mol Ther; 2016 Sep 29; 24(9):1615-26. PubMed ID: 27401038
    [Abstract] [Full Text] [Related]

  • 7. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.
    Blood; 2014 Apr 10; 123(15):2343-54. PubMed ID: 24596416
    [Abstract] [Full Text] [Related]

  • 8. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.
    PLoS One; 2016 Apr 10; 11(8):e0159477. PubMed ID: 27548616
    [Abstract] [Full Text] [Related]

  • 9. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.
    Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE.
    Clin Cancer Res; 2006 Feb 15; 12(4):1284-91. PubMed ID: 16489085
    [Abstract] [Full Text] [Related]

  • 10. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.
    Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.
    Leuk Res; 2014 Nov 15; 38(11):1367-73. PubMed ID: 25278187
    [Abstract] [Full Text] [Related]

  • 11. Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarker.
    Abdollahpour-Alitappeh M, Razavi-Vakhshourpour S, Abolhassani M.
    Biotechnol Appl Biochem; 2018 Nov 15; 65(6):841-847. PubMed ID: 29972607
    [Abstract] [Full Text] [Related]

  • 12. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
    Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grübler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hänggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Lüthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A.
    Cancer Immunol Res; 2024 Jul 02; 12(7):921-943. PubMed ID: 38683145
    [Abstract] [Full Text] [Related]

  • 13. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 14. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP.
    J Hematol Oncol; 2021 Sep 27; 14(1):155. PubMed ID: 34579739
    [Abstract] [Full Text] [Related]

  • 15. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, Bonnet D, Biagi E.
    Br J Haematol; 2013 May 27; 161(3):389-401. PubMed ID: 23432359
    [Abstract] [Full Text] [Related]

  • 16. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L, Liu X, Wang X, Sun Z, Song XT.
    Leuk Res; 2016 Feb 27; 41():76-84. PubMed ID: 26740053
    [Abstract] [Full Text] [Related]

  • 17. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, Gao F, Eades WC, Bonvini E, Chichili GR, Moore PA, Johnson S, Collins L, DiPersio JF.
    Blood; 2016 Jan 07; 127(1):122-31. PubMed ID: 26531164
    [Abstract] [Full Text] [Related]

  • 18. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 19. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
    Zhang Y, Park M, Ghoda LY, Zhao D, Valerio M, Nafie E, Gonzalez A, Ly K, Parcutela B, Choi H, Gong X, Chen F, Harada K, Chen Z, Nguyen LXT, Pichiorri F, Chen J, Song J, Forman SJ, Amanam I, Zhang B, Jin J, Williams JC, Marcucci G.
    J Hematol Oncol; 2024 Aug 14; 17(1):67. PubMed ID: 39143574
    [Abstract] [Full Text] [Related]

  • 20. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
    Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, von Bonin M, Ehninger A, Bachmann J, Ehninger G, Bornhäuser M, Bachmann MP.
    Blood Cancer J; 2015 Sep 18; 5(9):e348. PubMed ID: 26383821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.